Evidence map›Paper›PMID 39301699›Full record

ArticleHistology and histopathology2025

Expression feature and prognostic function of a novel immune checkpoint Siglec-15 in human colorectal cancer.

Guodong Liang, Linyun Zhou, Yang Fan, Run Ding, Junrong Yang, Li Xu, Yidan Zhu, Wen Huang

Abstract read
PubMed Publisher
In one paragraph

Article in Histology and histopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Guodong Liang *Department of Gastroenterology, Geriatric Hospital of Nanjing Medical University, Nanjing, China.
Linyun Zhou *Department of Radiology, Geriatric Hospital of Nanjing Medical University, Nanjing, China.
Yang FanDepartment of Medical Innovation Research, Hospital Management Institute, PLA General Hospital, Beijing, China.
Run DingDepartment of General Surgery, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Junrong YangDepartment of Pathology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Li XuDepartment of Pathology, Jiangsu Cancer Hospital, Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China.
Yidan ZhuDepartment of Gastroenterology, Geriatric Hospital of Nanjing Medical University, Nanjing, China. yue040605@sina.com.
Wen HuangDepartment of Oncology, The Fourth Affiliated Hospital of Nanjing Medical University, Nanjing, China. hwencn@163.com.

Funding

National Natural Science Foundation 82073389
6 · The paper itself

Abstract

backgroundSialic acid-bound immunoglobulin lectin 15 (Siglec-15) plays an important role in the development of cancer. However, the association between Siglec-15 expression and clinicopathological characteristics of colorectal cancer (CRC) has not been fully investigated.

methodsIn this present study, a number of bioinformatics analyses were performed to provide an overview and detailed characteristics of Siglec-15. Quantitative real-time polymerase chain reaction (qPCR), western blotting and immunohistochemistry analyses were conducted to characterize the expression of Siglec-15 in CRC. Kaplan-Meier survival and Cox regression analyses were performed to identify the prognostic parameters of CRC.

resultsThe results of bioinformatics analyses revealed the expression characteristics and prognostic roles of Siglec-15 in CRC. The data of qCPR, western blotting, and IHC analyses demonstrated that the expression of Siglec-15 in CRC tissues was significantly higher than that in non-cancerous tissues. Moreover, the expression level of Siglec-15 in CRC was significantly associated with lymph node metastasis (

conclusionsCollectively, the data suggested that Siglec-15 expression may serve as a novel prognostic factor and Siglec-15 might be identified as an ideal candidate for immunotherapy in CRC treatment.

Indexed as

Biomarkers, TumorColorectal NeoplasmsImmunoglobulinsLectinsAdultAgedFemaleHumansKaplan-Meier EstimateMaleMembrane ProteinsMiddle AgedPrognosisBiomarkers, TumorImmunoglobulinsLectinsMembrane ProteinsSIGLEC15 protein, human

Identifiers

PMID39301699

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.